Phosphate-Trapping Liposomes for Long-Term Management of Hyperphosphatemia
Hyperphosphatemia is a typical complication of end-stage renal disease, characterized by elevated and life-threatening serum phosphate levels. Hemodialysis does not enable sufficient clearance of phosphate, due to slow cell-to-plasma kinetics of phosphate ions; moreover, dietary restrictions and con...
Main Authors: | Chen Tzror-Azankot, Adi Anaki, Tamar Sadan, Menachem Motiei, Rachela Popovtzer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Materials |
Subjects: | |
Online Access: | https://www.mdpi.com/1996-1944/15/21/7779 |
Similar Items
-
Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
by: Li Li, et al.
Published: (2022-12-01) -
Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review
by: Steven N. Fishbane, et al.
Published: (2021-11-01) -
Ferric citrate for the treatment of hyperphosphatemia and iron deficiency anaemia in patients with NDD-CKD: a systematic review and meta-analysis
by: Xueying Ding, et al.
Published: (2024-03-01) -
Comparative Gut Microbiome Differences between Ferric Citrate and Calcium Carbonate Phosphate Binders in Patients with End-Stage Kidney Disease
by: Ping-Hsun Wu, et al.
Published: (2020-12-01) -
Enhanced oral bioavailability and tissue distribution of ferric citrate through liposomal encapsulation
by: Li Yuan, et al.
Published: (2017-01-01)